Articles related to Obstetrics & Gynecology

This 70-study meta analysis concludes that the evidence is moderate to high that bisphosphonates and denosumab reduce the risk for hip, vertebral, and other fractures. The evidence is moderate to high that abaloparatide and teriparatide reduce clinical fractures and radiographic vertebral fractures, and low to moderate that SERMs reduce radiographic vertebral fractures, but not clinical fractures.

Beyond the strong recommendation for bisphosponates as initial medical therapy in postmenopausal women with osteoporosis, the updated guidelines also suggest (not recommend) denosumab as second line therapy in women, bisphosphonates for osteoporosis in men, and romosozumab in women with very high risk of fractures. For the complete updated guideline, see Pharmacologic Treatment of Primary Osteoporosis or Low Bone Mass to Prevent Fractures in Adults: A Living Clinical Guideline From the American College of Physicians.

Yes, you read that right. According to a recent study in Scientific Reports, Chlamydia pneumoniae assaults the central nervous system by traveling up via the nose canal and into the brain. When the bacteria reach the brain, they encourage the production of amyloid beta protein, which is regarded to be a defining feature of dementia and Alzheimer’s disease.

The purpose of the randomized controlled study was to see what effect the green-MED diet will have on visceral fat tissue. The randomized controlled study, which lasted 18 months, involved 294 participants in all. Three groups of participants were created: the HDG (healthy dietary recommendations), the MED diet, and the green-MED diet. Participants in both MED groups consumed 440 mg of polyphenols and 28 g of walnuts daily. The green-MED group also ingested three to four cups of green tea daily, 100 g of frozen duckweed plant green smoothie, 800 mg of polyphenols daily, and less meat.

In a study of more than 800 rural-living men and women with knee osteoarthritis, an 18-month program of diet and exercise versus attention control yielded an average 14-pound greater weight loss in the test group – but not much difference in pain magnitude.

Today, it is possible to safely treat CML throughout pregnancy with little danger to the unborn child, as TKIs can now be safely administered during the later stages of pregnancy, according to new research. After beginning or continuing TKI therapy, a sizable majority of patients can be managed by observation alone, and disease control can be attained. IFN-α may be given in any trimester with little harm to the fetus if active treatment is necessary. Most essential, however, is a multidisciplinary strategy to offer clear and concise guidance to enable both the mother and the family to participate in the decision-making process.